Not a traditional drug phase: Calm room for Psychotic Disorders
This descriptive study aims primarily to characterize the sensory profile of patients in a closed psychiatric hospital unit who use a calming room. The main questions it aims to answer are : * Could sensory information processing disorders be the cause of distress and tension in these patients?
Official registry: https://clinicaltrials.gov/study/NCT06839950 · Centre Hospitalier Esquirol · enrollment listed as 80
What this phase means
This is an observational study. You are not assigned a new experimental drug. Researchers measure what already happens in your care or in daily life.
Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
What the registry says happens
This listing is observational (StudyType). The registry does not assign a new experimental drug as the study intervention.
They plan to enroll about 80 people at Limoges. Taking part typically means study visits and measurements plus check-ins.
Official title (unrewritten)
Sensory Profile and Early Clinical Signs of Calm Room Users
Interventions: Calm room
Primary outcome (registry wording): Scores of Sensory Sensitivity from the Adolescent/Adult Sensory Profile (Brown and Dunn, 2002) for users of the calming room and non-users of the calming room
Who it is for (from inclusion criteria)
- Ages 18 Years to 65 Years
- Gender and Age: Male or female, aged 18 to 65
- Hospitalization: Admitted to the closed hospitalization unit for less than 10 days
- Social security: Affiliated or beneficiary of a social security system
- Consent: Free, informed, and written consent, signed by the participant and/or their legal representative (for participants under protection measures) and the investigator (at the latest on the day of inclusion and before any research-related examination)
Who the registry excludes
- Inability to understand information related to the study
- Proven sensory disability
- Lack of social protection
- Previous Participation in this research protocol (in the case of a new hospitalization)
- Expression abilities incompatible with completing the AASP Scale (e.g., french language comprehension issues, mute individuals, patients in restraint and/or therapeutic isolation)
Public study contact (from the registry)
Aude Paquet, PhD in Psychology
aude.paquet@ch-esquirol-limoges.fr
Published on ClinicalTrials.gov. Contact them as a possible participant. They decide eligibility.
Sites listed on ClinicalTrials.gov
1 listed- Esquirol Hsopital Center — Limoges, New Aquitaine, France (recruiting)
FAQ about this NCT record
Is NCT06839950 still recruiting?
The sponsor posted status “Recruiting” on ClinicalTrials.gov at last ingest. Sites can pause independently. Confirm with the official record and the listed contact.
What phase is NCT06839950?
Not a traditional drug phase. Phase labels are FDA/ICH categories applied to the registry Phase field. They are not a finding that this study succeeded.
Can PlainTrials tell me if I qualify for NCT06839950?
No. The inclusion and exclusion lists on this page are readable extracts of the public eligibility block. Only the study team can screen you.
How to read a ClinicalTrials.gov record · Questions to ask the coordinator · Glossary